Next Article in Journal
Irritable Bowel Syndrome: Assessment of Prevalence and Risk Factors in Saudi University Students Using Rome IV Criteria
Previous Article in Journal
Screening Colonoscopy in Port Harcourt, Nigeria
 
 
Gastroenterology Insights is published by MDPI from Volume 11 Issue 1 (2020). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clarithromycin versus Levofloxacin-Based Regimens for Helicobacter Pylori Eradication in the Kurdistan Region of Iraq: A Randomized Clinical Trial

by
Shinah A. Mohammed
1,
Omer Q. B. Al-lela
1,*,
Nawfal R. Hussein
1,
Ramadhan S. Hajany
1 and
Laween S. Alduhoky
1
1
College of Pharmacy, University of Duhok, Duhok, Kurdistan Region
2
College of Pharmacy, University of Duhok, Duhok, Kurdistan Region; Department of Pharmacy, Al-Noor University College
3
College of Medicine, University of Zakho, Kurdistan Region
4
College of Medicine, University of Duhok, Duhok, Kurdistan Region
5
Azadi Teaching Hospital, Duhok, Kurdistan Region
*
Author to whom correspondence should be addressed.
Gastroenterol. Insights 2019, 10(1), 8256; https://doi.org/10.4081/gi.2019.8256
Submission received: 27 July 2019 / Accepted: 16 August 2019 / Published: 17 September 2019

Abstract

Helicobacter pylori infection is a predisposing factor for gastric cancer. This prospective, randomized clinical trial aimed to compare H. pylori eradication rates associated with a clarithromycin-based regimen and levofloxacin-based regimen. H. pylori infection was confirmed by a rapid urease test during endoscopy and its eradication by a urea breath test. In this study, 192 patients were recruited; 93 patients received a clarithromycin- based regimen and 99 a levofloxacin- based regimen. Sixty-four patients completed the clarithromycinbased regimen and 60 the levofloxacinbased regimen. The eradication success rate of the clarithromycin-based regimen was 52/64 (81.25%), while that of the levofloxacin- based regimen was 49/60 (81.6%) (P=0.9524; odds ratio [OR]=1.0280; confidence interval [CI]=0.4153-2.5447). Investigation of the risk factors associated with treatment failure showed that the overall efficacy of the regimens was influenced by body mass index (BMI), with a high failure rate observed in patients with a high BMI (P=0.0174; OR=1.1116; CI=1.0187- 1.2129). Age, sex, endoscopic diagnosis and smoking did not influence treatment outcomes. Further studies are needed to monitor H. pylori antibiotic resistance rates.
Keywords: Helicobacter pylori; Eradication; Levofloxacin; Clarithromycin; Duhok; Iraq Helicobacter pylori; Eradication; Levofloxacin; Clarithromycin; Duhok; Iraq

Share and Cite

MDPI and ACS Style

Mohammed, S.A.; Al-lela, O.Q.B.; Hussein, N.R.; Hajany, R.S.; Alduhoky, L.S. Clarithromycin versus Levofloxacin-Based Regimens for Helicobacter Pylori Eradication in the Kurdistan Region of Iraq: A Randomized Clinical Trial. Gastroenterol. Insights 2019, 10, 8256. https://doi.org/10.4081/gi.2019.8256

AMA Style

Mohammed SA, Al-lela OQB, Hussein NR, Hajany RS, Alduhoky LS. Clarithromycin versus Levofloxacin-Based Regimens for Helicobacter Pylori Eradication in the Kurdistan Region of Iraq: A Randomized Clinical Trial. Gastroenterology Insights. 2019; 10(1):8256. https://doi.org/10.4081/gi.2019.8256

Chicago/Turabian Style

Mohammed, Shinah A., Omer Q. B. Al-lela, Nawfal R. Hussein, Ramadhan S. Hajany, and Laween S. Alduhoky. 2019. "Clarithromycin versus Levofloxacin-Based Regimens for Helicobacter Pylori Eradication in the Kurdistan Region of Iraq: A Randomized Clinical Trial" Gastroenterology Insights 10, no. 1: 8256. https://doi.org/10.4081/gi.2019.8256

APA Style

Mohammed, S. A., Al-lela, O. Q. B., Hussein, N. R., Hajany, R. S., & Alduhoky, L. S. (2019). Clarithromycin versus Levofloxacin-Based Regimens for Helicobacter Pylori Eradication in the Kurdistan Region of Iraq: A Randomized Clinical Trial. Gastroenterology Insights, 10(1), 8256. https://doi.org/10.4081/gi.2019.8256

Article Metrics

Back to TopTop